QURE icon

uniQure

17.92 USD
+2.54
16.51%
At close Updated Apr 13, 4:00 PM EDT
Pre-market
After hours
17.91
-0.01
0.06%
1 day
16.51%
5 days
3.11%
1 month
15.39%
3 months
-16.65%
6 months
-71.11%
Year to date
-23.39%
1 year
95.42%
5 years
-48.62%
10 years
40.11%
 

About: uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases. Its program and pipeline involves: Huntington's Disease, Temporal Lobe Epilepsy (TLE), Fabry Disease, ALS (SOD1), Hemophilia B, Clinical Trials, and Research Programs.

Employees: 221

0
Funds holding %
of 8,115 funds
0
Analysts bullish %
of 8 analysts
0
Positive news %
of 127 articles
Price charts implemented using Lightweight Charts™